Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
AUTOR(ES)
Lopes, Edmundo P.A., Valente, Lucila M., Silva, A. Eduardo B., Kirsztajn, Gianna Mastroianni, Cruz, Cibele N., Ferraz, Maria Lucia G
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2003-10
RESUMO
We describe a treatment made with interferon-alpha (IFN-alpha) plus ribavirin of two patients with membranoproliferative glomerulonephritis (MPGN) induced by hepatitis C virus (HCV): Case 1 was a 22-year-old woman with leg and facial edema, hypertension and proteinuria, whose liver biopsy revealed chronic active hepatitis; and Case 2 was a 42-year-old man with anasarca, hypertension and proteinuria, whose liver biopsy indicated cirrhosis. Both had anti-HCV, HCV-RNA and cryoglobulins. IFN-alpha (3 million units (MU), 3 times/week) and ribavirin (1 g/day) were administered for 12 months. The drugs were well tolerated by both patients. Serum alanine aminotransferase (ALT) levels normalized and HCV-RNA became negative. Cryoglobulins disappeared and an improvement in renal disease was seen after 6 months of therapy. However, after 9 months, Case 2 presented ALT elevation, and proteinuria was detected. Two years after the end of therapy, both patients were negative in repeated HCV-RNA and cryoglobulin tests. Case 1 was asymptomatic, with normal liver and renal tests, and Case 2 had normal blood pressure, with mild edema of the ankles. Based on the evolution of these two cases, the association of IFN-alpha and ribavirin may be a therapeutic option for patients with MPGN related to HCV.
Documentos Relacionados
- Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy
- Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
- Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin: a review
- Interferon-alpha receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-alpha therapy of patients with chronic hepatitis C
- Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment.